PharmaEngine, Inc. (TPEX: 4162)
Taiwan
· Delayed Price · Currency is TWD 99.90
-1.60 (-1.58%)
Nov 15, 2024, 1:30 PM CST
PharmaEngine Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 831.92 | 767.67 | 654.38 | 654.84 | 1,056 | 314.04 | Upgrade
|
| Revenue Growth (YoY) | 12.60% | 17.31% | -0.07% | -37.99% | 236.27% | 7.02% | Upgrade
|
| Cost of Revenue | 46.11 | 48.7 | 49.7 | 37.07 | 37.23 | 31.8 | Upgrade
|
| Gross Profit | 785.81 | 718.97 | 604.68 | 617.76 | 1,019 | 282.24 | Upgrade
|
| Selling, General & Admin | 134.31 | 131.51 | 140.06 | 118.4 | 113.35 | 118.84 | Upgrade
|
| Research & Development | 258.75 | 310.28 | 181.88 | 136.89 | 95.73 | 130.79 | Upgrade
|
| Operating Expenses | 393.06 | 441.79 | 321.95 | 255.07 | 209.07 | 249.63 | Upgrade
|
| Operating Income | 392.75 | 277.18 | 282.74 | 362.69 | 809.71 | 32.61 | Upgrade
|
| Interest Expense | -0.21 | -0.31 | -0.08 | -0.21 | -0.44 | -0.11 | Upgrade
|
| Interest & Investment Income | 67.24 | 54.32 | 25.57 | 15.42 | 41.61 | 67.87 | Upgrade
|
| Currency Exchange Gain (Loss) | -8.88 | -2.13 | 8.8 | -15.68 | -107.06 | -43.18 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.18 | - | 0.03 | 0.31 | 8.66 | -7.52 | Upgrade
|
| EBT Excluding Unusual Items | 447.72 | 329.06 | 317.06 | 362.53 | 752.48 | 49.67 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 5.53 | 45.46 | 0.82 | - | - | Upgrade
|
| Other Unusual Items | 3.39 | 3.39 | 29.95 | 182.04 | - | - | Upgrade
|
| Pretax Income | 451.1 | 337.97 | 392.47 | 545.4 | 752.48 | 49.67 | Upgrade
|
| Income Tax Expense | 80.96 | 63.32 | 73.68 | 119.36 | 148.19 | 7.12 | Upgrade
|
| Net Income | 370.14 | 274.65 | 318.78 | 426.03 | 604.28 | 42.55 | Upgrade
|
| Net Income to Common | 370.14 | 274.65 | 318.78 | 426.03 | 604.28 | 42.55 | Upgrade
|
| Net Income Growth | 27.24% | -13.84% | -25.17% | -29.50% | 1320.17% | -67.11% | Upgrade
|
| Shares Outstanding (Basic) | 144 | 144 | 144 | 145 | 146 | 146 | Upgrade
|
| Shares Outstanding (Diluted) | 144 | 144 | 144 | 145 | 146 | 146 | Upgrade
|
| Shares Change (YoY) | 0.03% | 0.03% | -0.72% | -0.80% | 0.11% | -1.27% | Upgrade
|
| EPS (Basic) | 2.58 | 1.91 | 2.22 | 2.95 | 4.15 | 0.29 | Upgrade
|
| EPS (Diluted) | 2.57 | 1.91 | 2.22 | 2.94 | 4.14 | 0.29 | Upgrade
|
| EPS Growth | 27.23% | -13.96% | -24.49% | -28.99% | 1327.59% | -67.02% | Upgrade
|
| Free Cash Flow | 409.98 | 256.56 | 198.57 | 929.44 | 64.77 | 15.87 | Upgrade
|
| Free Cash Flow Per Share | 2.85 | 1.78 | 1.38 | 6.42 | 0.44 | 0.11 | Upgrade
|
| Dividend Per Share | 1.500 | 1.500 | 2.000 | 2.700 | 2.500 | 0.500 | Upgrade
|
| Dividend Growth | -25.00% | -25.00% | -25.93% | 8.00% | 400.00% | -50.00% | Upgrade
|
| Gross Margin | 94.46% | 93.66% | 92.41% | 94.34% | 96.47% | 89.87% | Upgrade
|
| Operating Margin | 47.21% | 36.11% | 43.21% | 55.39% | 76.68% | 10.38% | Upgrade
|
| Profit Margin | 44.49% | 35.78% | 48.72% | 65.06% | 57.22% | 13.55% | Upgrade
|
| Free Cash Flow Margin | 49.28% | 33.42% | 30.34% | 141.94% | 6.13% | 5.05% | Upgrade
|
| EBITDA | 394.31 | 278.55 | 283.44 | 363.39 | 811.29 | 35.58 | Upgrade
|
| EBITDA Margin | 47.40% | 36.28% | 43.31% | 55.49% | 76.83% | 11.33% | Upgrade
|
| D&A For EBITDA | 1.56 | 1.37 | 0.71 | 0.7 | 1.58 | 2.97 | Upgrade
|
| EBIT | 392.75 | 277.18 | 282.74 | 362.69 | 809.71 | 32.61 | Upgrade
|
| EBIT Margin | 47.21% | 36.11% | 43.21% | 55.39% | 76.68% | 10.38% | Upgrade
|
| Effective Tax Rate | 17.95% | 18.74% | 18.77% | 21.89% | 19.69% | 14.33% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.